What is your approach to determining fitness for patients to undergo CAR-T therapy for relapsed/refractory multiple myeloma, and any absolute perceived contraindications for CAR-T?

This is a great question to which the only truly correct answer is, "It depends." Not just on the patient & disease biology, of course, but also the year in which the question is answered. For example, right now there are patients for whom commercial cilta-cel or ide-cel are not appropriate because of long vein-to-vein times in the 6-8 week range. There are ongoing trials of rapid-manufacturing autologous products such as GC012F and PHE885 (durca-cel) that will completely change this paradigm if they come to market in the future. Allogeneic "off-the-shelf" CAR products from healthy donors will change this as well. Conversely, once belantamab mafodotin is re-approved based on DREAMM-7 and DREAMM-8, the question will re-emerge of how long one...